Pancreatic Cancer Pipeline Reaches New Milestone with 200+ Therapies from 170+ Companies Advancing Novel Treatment Approaches
核心洞察
DelveInsight (搜索)'s latest analysis reveals over 170 companies are developing more than 200 pipeline therapies for pancreatic cancer (搜索), marking significant expansion in the treatment landscape.
Advanced candidates include TQB2868, a PD-1 (搜索)/TGF-β (搜索) bifunctional fusion protein in Phase III development, and Trabedersen, an antisense oligodeoxynucleotide in Phase II/III trials.
Recent regulatory milestones include FDA approval of OPTUNE Pax (搜索) for locally advanced pancreatic cancer (搜索) and Orphan Drug Designation for daraxonrasib from Revolution Medicines.
The pancreatic cancer (搜索) therapeutic landscape is experiencing unprecedented growth, with DelveInsight (搜索)'s latest pipeline analysis revealing over 170 companies advancing more than 200 pipeline therapies across multiple development stages. This robust pipeline represents a significant expansion in efforts to address one of oncology's most challenging malignancies, which maintains a five-year survival rate of approximately 13%.
Advanced Pipeline Candidates Show Promise
Among the most advanced candidates, TQB2868 stands out as a novel PD-1 (搜索)/TGF-β (搜索) bifunctional fusion protein currently in Phase III clinical development. The therapy is designed to simultaneously inhibit immune checkpoint pathways and modulate the tumor microenvironment by targeting both PD-1/PD-L1 (搜索) signaling and TGF-β activity, aiming to enhance anti-tumor immune responses and overcome immune suppression.
Trabedersen (OT-101) represents another significant advancement in Phase II/III development. This antisense oligodeoxynucleotide targets TGF-β2 (搜索) mRNA, effectively reducing its expression and restoring immune system activity against tumor cells. Clinical studies have demonstrated encouraging safety profiles and long-term disease control in patients with pancreatic cancer (搜索).
Antroquinonol, a novel small molecule Ras (搜索) inhibitor, offers a convenient oral administration option and has received Orphan Drug Designation from the FDA. The therapy inhibits Ras signaling pathways, leading to autophagy-induced cancer cell death, and is currently in Phase II clinical evaluation.
Recent Regulatory and Clinical Milestones
The pipeline has achieved several notable regulatory milestones in recent months. In February 2026, the FDA approved OPTUNE Pax (搜索) for the treatment of adult patients with locally advanced pancreatic cancer (搜索) concomitant with gemcitabine and nab-paclitaxel. Additionally, in October 2025, the U.S. FDA granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer.
ChipScreen Biosciences (搜索) received regulatory approval from China's National Medical Products Administration (NMPA) in January 2026 to initiate a new clinical trial for chiauranib in pancreatic cancer (搜索). Revolution Medicines has also made significant progress, announcing nine oral and poster presentations highlighting advances across its RAS (搜索)(ON) inhibitor pipeline, including daraxonrasib, at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Diverse Therapeutic Approaches and Company Landscape
The competitive landscape includes a wide range of global innovators such as Alligator Bioscience (搜索), ChipScreen Biosciences (搜索), Revolution Medicines, Marker Therapeutics, NanoPharmaceuticals, Beijing Biotech, Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Bristol Myers Squibb (搜索), AstraZeneca, and Arcus Biosciences, among others.
Key areas of focus include dual-target immunotherapies, antibody-drug conjugates (ADCs), and cell-based treatments specifically designed to overcome the protective tumor microenvironment that characterizes pancreatic cancer (搜索). The pipeline features therapies across multiple routes of administration, including intra-articular, intraocular, intrathecal, intravenous, oral, parenteral, subcutaneous, topical, and transdermal delivery methods.
Precision Oncology Focus
The current pipeline emphasizes precision oncology approaches with therapies categorized by molecule types including oligonucleotides, peptides, and small molecules. Companies are developing both monotherapy and combination therapy approaches, with therapeutic assessment spanning discovery through Phase III clinical stages.
Promising pipeline therapies showing strong potential include Chiauranib, Albumin-bound paclitaxel, Gemcitabine, Zimberelimab, Quemliclustat, Onvansertib, and Nanoliposomal irinotecan, among others. These candidates represent diverse mechanisms of action targeting various aspects of pancreatic cancer (搜索) biology and the tumor microenvironment.
The robust pipeline development reflects the industry's commitment to addressing significant unmet clinical needs in pancreatic cancer (搜索) treatment, with companies pursuing innovative approaches to improve outcomes for patients facing this aggressive malignancy.